https://orcid.org/0000-0002-6594-9271
References
- Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2020;9(1):22.
- Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J Am Med Assoc. 2004 Dec 1;292(21):2585–2590. DOI:10.1001/jama.292.21.2585
- Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol. 2017 Apr 1;23(3):149–154. DOI:10.1097/RHU.0000000000000497
- Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011 Mar;63(3):713–721.
- Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016 Feb 18;374(7):664–669. DOI:10.1056/NEJMra1515161
- Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb. 2005;12(3):121–131. DOI:10.5551/jat.12.121
- Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl- coenzyme a reductase-associated autoimmune myopathy. Arthritis Care Res. 2012 Aug;64(8):1233–1237.
- Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014 Jan;24(1):4–15.
- Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–1616. DOI:10.1016/j.jacc.2009.04.053
- Babu S, Li Y. Statin induced necrotizing autoimmune myopathy. InternetAvailable from J Neurol Sci. 2015;3511–2:13–17. http://dx.doi.org/10.1016/j.jns.2015.02.042
- Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016;68(2):234–235. InternetAvailable from. DOI:http://dx.doi.org/10.1016/j.jacc.2016.04.037
- Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96(4):470–476. DOI:10.1038/clpt.2014.121
- Visseren FLJ, MacH F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. DOI:10.1093/eurheartj/ehab484
- Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–1639. InternetAvailable from. DOI:http://dx.doi.org/10.1016/S0140-6736(10)60545-4
- Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012 Feb;64(2):269–272.
- Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018 Jan 1;28(1):87–99.
- Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010 Feb;41(2):185–190.